Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 15.33 USD 0.72% Market Closed
Market Cap: 824.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Prothena Corporation PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prothena Corporation PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Revenue
$133.4m
CAGR 3-Years
-13%
CAGR 5-Years
178%
CAGR 10-Years
11%
Alkermes Plc
NASDAQ:ALKS
Revenue
$1.5B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
10%
Amarin Corporation PLC
NASDAQ:AMRN
Revenue
$241m
CAGR 3-Years
-26%
CAGR 5-Years
-8%
CAGR 10-Years
18%
No Stocks Found

Prothena Corporation PLC
Revenue Breakdown

Breakdown by Geography
Prothena Corporation PLC

Not Available

Breakdown by Segments
Prothena Corporation PLC

Total Revenue: 91.4m USD
100%
Collaboration Revenue: 91.3m USD
99.9%
Revenue From License And Intellectual Property: 50k USD
0.1%

Prothena Corporation PLC
Glance View

Market Cap
824.9m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
36.55 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Revenue?
Revenue
133.4m USD

Based on the financial report for Sep 30, 2024, Prothena Corporation PLC's Revenue amounts to 133.4m USD.

What is Prothena Corporation PLC's Revenue growth rate?
Revenue CAGR 10Y
11%

Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for Prothena Corporation PLC have been -13% over the past three years , 178% over the past five years , and 11% over the past ten years .

Back to Top